For example, LOX-PP reverts the invasive phenotype of breast cancer cells [34], inhibits the transformed phenotype of lung and pancreatic cancer cells [35], interferes with FAK activation in breast cancer cells [54] and inhibits prostate cancer cell growth by targeting FGF-2 cell binding and signalling [55]. This evidence concerns the gene FGF2 and pancreatic neoplasm.